Chronic Obstructive Pulmonary Disease (COPD): From Diagnosis and Comorbidities to Personalized Management and Palliative Care

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Methodology, Drug and Device Discovery".

Deadline for manuscript submissions: 10 December 2024 | Viewed by 1068

Special Issue Editors


E-Mail Website
Guest Editor
1. Associate Professor, Palliative Medicine Department, Iuliu Hatieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania
2. Associate Professor, Pneumology Department, “Leon Daniello” Clinic of Pneumophtisiology, 400371 Cluj-Napoca, Romania
Interests: obstructive respiratory diseases; phenotypes; inhaler barriers; adherence issues; bronchiectasis; mycobacteriosis; interstitial lung diseases; palliative care

E-Mail Website
Guest Editor
1. Department of Pulmonology II, Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania
2. Marius Nasta Institute of Pneumology, 050159 Bucharest, Romania
Interests: smoke free environments; obstructive respiratory diseases; sleep apnea; noninvasive ventilation; bronchiectasis; adherence issues; interstitial lung diseases
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Much research has been conducted on the topic of COPD over the years. However, much remains to be understood, including in academic research, where genomics, epigenomics and metabolomics are current popular topics all over the world. Challenges also remain in the clinical and functional fields, in which early COPD is an entity that has been brought back into discussion from perspectives aimed at its prevention and even therapeutic strategies. The identification and treatment of COPD comorbidities represent other concerns that researchers and clinicians face in their daily practice. The impact of COPD on patients and their families is multidimensional. The personalized holistic management of the disease is an approach that all healthcare professionals must become familiar with. This Special Issue dedicated to COPD is an invitation to explore the complex dimensions that this disease entails by publishing original research and literature reviews from specialists that diagnose, treat and care for these patients throughout the course of the disease.

Dr. Ruxandra Mioara Râjnoveanu
Prof. Dr. Florin Mihaltan
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • risk factors
  • systemic inflammation
  • phenotypes
  • cardio-pulmonary functional assessment
  • comorbidities
  • exacerbations
  • treatment
  • rehabilitation
  • prognosis tools
  • palliative care
  • management

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

14 pages, 441 KiB  
Review
Opioids in Treatment of Refractory Dyspnea in Chronic Obstructive Pulmonary Disease: Yes, No or Maybe
by Ruxandra-Mioara Rajnoveanu, Antonia Harangus, Doina Adina Todea, Milena Adina Man, Corina Eugenia Budin and Armand-Gabriel Rajnoveanu
J. Pers. Med. 2024, 14(3), 318; https://doi.org/10.3390/jpm14030318 - 19 Mar 2024
Viewed by 868
Abstract
Chronic Obstructive Pulmonary Disease (COPD) is a complex condition with significant impact on prognosis, especially in advanced stages where symptom burden becomes critical. Breathlessness affects patients’ quality of life, and despite various therapeutic strategies, the role of opioids in palliative care for COPD [...] Read more.
Chronic Obstructive Pulmonary Disease (COPD) is a complex condition with significant impact on prognosis, especially in advanced stages where symptom burden becomes critical. Breathlessness affects patients’ quality of life, and despite various therapeutic strategies, the role of opioids in palliative care for COPD remains under investigation. The acceptance of a therapeutic trial of different types of opioids is increasing not only in end-of-life situations but also for stable COPD patients experiencing intolerable refractory breathlessness despite optimal conventional therapy. Recent clinical trials have raised questions about the overall clinical benefit of opioids in addressing breathlessness in COPD, prompting the need to clarify inconsistencies and identify specific subgroups that may benefit from opioid therapy. In the clinical setting, it is crucial to understand the attributes of patients who exhibit positive responses to opioids and what type of opioids could have a positive impact. This research paper aims to offer an update of the most recent evidence of opioid treatment in managing breathlessness among individuals with COPD with a head-to-head evaluation of the supporting and opposing proof in the medical literature. Full article
Show Figures

Figure 1

Back to TopTop